In response to: “Reply to research letter”

Podobne zapisy

• Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
  od: Wan, Marilyn T., i wsp.
  Wydane: (2020)
• Reply to research letter
  od: Rivera-Oyola, Ryan, i wsp.
  Wydane: (2020)
• The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  od: Wan, Marilyn T., i wsp.
  Wydane: (2020)
• The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  od: Syed, Maha N., i wsp.
  Wydane: (2020)
• Commentary
  od: Shin, Daniel B., i wsp.
  Wydane: (2021)